T1	Participants 20 76	persons with cystic fibrosis and the G551D-CFTR mutation
T2	Participants 112 140	treatment of cystic fibrosis
T3	Participants 395 460	39 adults with cystic fibrosis and at least one G551D-CFTR allele
T4	Participants 705 752	group of subjects who received 150 mg of VX-770
T5	Participants 1332 1376	None of the subjects withdrew from the study
T6	Participants 1390 1428	dverse events occurred in two subjects
T7	Participants 1754 1807	within-subject improvements in CFTR and lung function
T8	Participants 1893 1933	CFTR as a means to treat cystic fibrosis
